The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 1 of the 19 sources its claims cite were checked for support.
Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program
Open accessAbstract
Insulin resistance and beta-cell dysfunction, two factors central to the pathogenesis of type 2 diabetes, were studied in relation to the development of diabetes in a group of participants with impaired glucose tolerance in the Diabetes Prevention Program (DPP) at baseline and after specific interventions designed to prevent diabetes. Participants were randomly assigned to placebo (n = 1,082), metformin (850 mg twice a day) (n = 1,073), or intensive lifestyle intervention (n = 1,079). The diabetes hazard rate was negatively associated with baseline insulin sensitivity (hazard rate ratio = 0.62-0.94 per SD difference, depending on treatment group and measure of sensitivity) and with baseline insulin secretion (hazard rate ratio = 0.57-0.76 per SD). Improvements in insulin secretion and insulin sensitivity were associated with lower hazard rates in all treatment arms (hazard rate ratio = 0.46-0.95 per SD increase and 0.29-0.79 per SD increase, respectively). In multivariate models that included the three metabolic variables (changes in body weight, insulin sensitivity, and insulin secretion) each significantly and independently predicted progression to diabetes when adjusted for the other two variables. The intensive lifestyle intervention, which elicited the greatest reduction in diabetes incidence, produced the greatest improvement in insulin sensitivity and the best preservation of beta-cell function after 1 year, whereas the placebo group, which had the highest diabetes incidence, had no significant change in insulin sensitivity and beta-cell function after 1 year. In the metformin group, diabetes risk, insulin sensitivity, and beta-cell function at 1 year were intermediate between those in the intensive lifestyle and placebo groups. In conclusion, higher insulin secretion and sensitivity at baseline and improvements in response to treatment were associated with lower diabetes risk in the DPP. The better preventive effectiveness of intensive lifestyle may be due to improved insulin sensitivity concomitant with preservation of beta-cell function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Own result · 15 Own interpretation · 10 No full text of the sources · 4 No basis given · 2 Own method · 1 Partly supported · 1 Sources not found · 1 Not checked yet · accuracy not yet measured
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Correlations between the year 1 changes in metabolic variables were similar among the treatment groups, except for the correlations between 1/fasting insulin and either CIR or IGR, which were higher in the metformin group.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvements in insulin secretion and insulin sensitivity were associated with lower hazard rates in all treatment arms (hazard rate ratio ؍ 0.46 -0.95 per SD increase and 0.29 -0.79 per SD increase, respectively).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard rates for developing diabetes were positively associated with baseline fasting plasma glucose, 120-min plasma glucose, and A1C (Fig. 3).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Prediction of diabetes by individual metabolic factors
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this large cohort of individuals with IGT, our results clearly confirm this relationship because each variable had an independent effect on the risk of developing diabetes.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fasting and 30-and 120-min glucose values decreased significantly in the lifestyle group”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“this change was relatively less than the change in insulin sensitivity”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas the placebo group, which had the highest diabetes incidence, had no significant change in insulin sensitivity and -cell function after 1 year.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and with baseline insulin secretion (hazard rate ratio ؍ 0.57-0.76per SD).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the lifestyle and placebo groups, hazard rates were negatively associated with baseline 1/fasting insulin.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Baseline and changes in body weight, insulin sensitivity, and insulin secretion.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard rates for diabetes were positively associated with baseline weight in the lifestyle and placebo groups when adjusted for baseline demographics (age, sex, and race/ethnicity) (Fig. 4, left panels).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Baseline and changes in body weight, insulin sensitivity, and insulin secretion.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 7
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The latter two are strong risk factors for type 2 diabetes (1-6).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
What the sources say
- Not checked — no full text of the sourcecites [1] The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403,2002 source
- Partly supportedcites [2] Modan M, Karasik A, Halkin H, Fuchs Z, Lusky A, Shitrit A, Modan B: Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response: the Israel study of glucose intolerance, obesity and hypertension. Diabetologia 29:82–89,1986 sourceExperimental — accuracy not yet measured
The BMI INTERVAL section describes impaired glucose tolerance progressing to Type 2 diabetes, and the Discussion likewise describes worsening from impaired tolerance to diabetes. But the paper does not address impaired fasting glycemia or establish that both conditions are strong risk factors. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [3] Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500–1506,1988 source
- Not checked — no full text of the sourcecites [4] Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C: Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217–1225,1988 source
- Not checked — no full text of the sourcecites [5] Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46:701–710,1997 source
- Not checked — no full text of the sourcecites [6] Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group: β-Cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. Diabetes 51:2170–2178,2002 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 1 year, there was less reduction in fasting insulin in the metformin than in the lifestyle group, with the lifestyle participants having the greatest reduction throughout all years of follow-up.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ISI and 1/fasting insulin were, as expected, highly correlated at baseline (Spearman r ϭ 0.99).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > July 2001 (see DATA ANALYSIS).
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Encompassing of the additional follow-up data yielded risk reductions (95% CI) of developing diabetes of 30% (16 -41%) for metformin and 55% (45-63%) for lifestyle, each compared with placebo.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > July 2001 (see DATA ANALYSIS).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, we found that A1C, proinsulin, insulin sensitivity, and insulin secretion also predicted the development of diabetes in these high-risk individuals.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among all participants, including those who developed diabetes, fasting glucose, insulin, and proinsulin concentrations were significantly lower than placebo at the first annual visit in the metformin and the lifestyle groups and increased during the 2nd and 3rd years, with the levels remaining significantly lower than in the placebo group (Fig. 2).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the placebo group, however, there was a significant increase in 30-min and a significant decrease in the 120-min glucose levels.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas lifestyle and metformin treatments reduced the incidence of diabetes, they did not change the independent effects of insulin sensitivity and secretion on the risk for diabetes, so that those individuals with the lowest sensitivity and secretion within each treatment group still had the greatest risk, whereas those with the highest insulin sensitivity and secretion had uniformly low risk”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Changes in weight and proinsulin over time were strong predictors of diabetes, with decreased weight and decreased proinsulin predicting a lower hazard of diabetes in all treatment arms (Fig. 4B and D).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Baseline and changes in body weight, insulin sensitivity, and insulin secretion.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The metformin group showed a more modest improvement in insulin sensitivity (ISI and 1/fasting insulin, P Ͻ 0.001) with a significant decrease in insulin secretion (IGR, P Ͻ 0.001)”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, improved insulin sensitivity was also associated with a decrease in the risk of developing diabetes, with the lifestyle intervention again being the most effective.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, in the placebo group there were no significant changes in either estimate of insulin sensitivity, a significant decrease in insulin secretion (IGR, P ϭ 0.03) but no significant change in -cell function”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The intensive lifestyle intervention, which elicited the greatest reduction in diabetes incidence, produced the greatest improvement in insulin sensitivity and the best preservation of -cell function after 1 year”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The lifestyle group had the greatest improvement in insulin sensitivity (ISI and 1/fasting insulin, P Ͻ 0.001), and this was associated with a significant decrease in insulin secretion (IGR, P ϭ 0.008).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relationships in the current data were not hyperbolic but were well described as nonlinear.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of developing diabetes was lowest among participants in the lifestyle arm, intermediate among those assigned to metformin, and highest among placebo participants across the range of baseline glycemic variables.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Prediction of diabetes by individual metabolic factors
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, these treatment effects were seen regardless of the categories of sensitivity and secretion, except in the lowest risk categories (high insulin sensitivity and secretion), in which hazard rates were uniformly low.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Prediction of diabetes by multiple metabolic factors Baseline insulin sensitivity and insulin secretion.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“found that the risk for developing type 2 diabetes was reduced by 58 and 31% in the intensive lifestyle and metformin-treated groups, respectively, compared with the placebo-treated group (1).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
What the sources say
- Not checked — no full text of the sourcecites [1] The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403,2002 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings are compatible, with lifestyle having the greatest effect to preserve -cell function and it being the more effective intervention to reduce the rate of development of diabetes.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, a decrease in -cell function would be characterized by a shift to the left of or below the curve.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, it would appear that -cell function was unchanged in the lifestyle intervention group while declining in the control group.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Ninety-five percent of participants completed their first annual visit.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Table 1 presents baseline characteristics by treatment group.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This hyperbolic relationship has previously been described when more direct measures of insulin secretion and sensitivity were used (29).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [29] Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and B-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672,1993 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Lifestyle intervention and, to a lesser extent, metformin enhanced -cell function and improved insulin sensitivity, leading to a reduced risk for developing diabetes.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The baseline relationship between insulin secretion and insulin sensitivity is the same across treatment groups.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus it appears that whereas change in body weight was a strong predictor of the risk of developing diabetes in the DPP, the interventions probably had differential effects on other variables or direct effects in the liver or muscle even after accounting for insulin secretion.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Similar findings of the effect of lifestyle intervention have been reported for the Finnish Diabetes Prevention Study (30).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [30] Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindström J, Tuomilehto J, Finnish Diabetes Prevention Study Group: Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52:2532–2538,2003 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but whereas the absolute response declined, this decrease was not as large as might be expected from the concomitant change in insulin sensitivity and therefore can be interpreted as improved secretion relative to sensitivity.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“this process is never complete so that not all proinsulin molecules are cleaved, resulting in a small quantity of proinsulin being secreted along with insulin and C-peptide (36 -38).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [36] Kitabchi AE: Proinsulin and C-peptide a review. Metabolism 26:547–587,1977 source
- Not checked — no full text of the sourcecites [37] Mykkanen L, Haffner SM, Hales CN, Ronnemaa T, Laakso M: The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 46:1990–1995,1997 source
- Not checked — no full text of the sourcecites [38] Reaven GM, Chen Y-DI, Hollenbeck CB, Sheu WHH, Ostrega D, Polonsky KS: Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 76:44–48,1993 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The effect of metformin and intensive lifestyle in reducing the incidence of diabetes is related in part to their ability to shift the relationship between insulin sensitivity and insulin secretion in a direction compatible with an improvement in -cell function, with lifestyle being more effective in doing so.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The baseline relationship between insulin secretion and insulin sensitivity is the same across treatment groups.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
In the paper
“production of insulin is dependent on the proteolytic processing in the -cell secretory granule of proinsulin to insulin and C-peptide (35).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [35] Duckworth WC, Kitabchi AE, Heinemann M: Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 53:418–427,1972 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The authors state this as an assumption.
Hazard ratios were constant over time.
“Hazard ratios were assumed to be constant over time.”
The paper relies on this without support.
Deterioration of either insulin sensitivity or insulin secretion is critical in determining the progression of hyperglycemia.
“Although the relative importance of decreased insulin sensitivity and insulin secretion in the pathogenesis of type 2 diabetes has been debated, it is generally accepted that deterioration of either or both is critical in determining the progression of hyperglycemia.”
The paper relies on this without support.
Insulin resistance and β-cell dysfunction are central characteristics of type 2 diabetes, impaired fasting glycemia, and impaired glucose tolerance.
“Insulin resistance and -cell dysfunction are two well-established characteristics of type 2 diabetes, impaired fasting glycemia, and impaired glucose tolerance (IGT).”
The paper relies on this without support.
The baseline relationship between insulin secretion and insulin sensitivity is the same across treatment groups.
“The curve represents the regression line of the logarithm of estimated insulin secretion as a linear function of the logarithm of estimated insulin sensitivity for all participants at baseline.”
The paper relies on this without support.
The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
“changes in insulin secretion may reflect one of three scenarios regarding -cell function.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Diabetes Prevention Program (DPP), greater baseline β-cell function and insulin sensitivity contributed independently to the restoration of NGT following lifestyle changes ( 65 , 66 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, higher diabetes incidence in all treatment groups was found among individuals with lower measures of insulin secretory response at baseline in the DPP (22).”
From Increased genetic risk for β-cell failure is associated with β-cell function decline in people with prediabetes (2024) · cites this paper as [22]
In the citing paper
“Successful lifestyle interventions seem to improve insulin sensitivity and β-cell function.92,93”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [93]
In the citing paper
“Since insulin resistance could increase the risk of AD through both cerebrovascular and Aβ related mechanisms [23]”
From Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial (2016) · cites this paper as [23]
In the citing paper
“Large intervention studies with lifestyle interventions and drugs like metformin have shown that it is feasible to decrease hyperinsulinemia and the risk of diabetes (The Diabetes Prevention Program Research, 2005) and is possible that these interventions could extend to decreasing the risk of Alzheimer’s disease.”
From Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease (2008) · cites this paper as The Diabetes Prevention Program Research, 2005
In the citing paper
“Studies showing that metformin (MET) not only reduces insulin levels (11), inflammation and thrombosis (12), and the risk of the metabolic syndrome (13), but also improves insulin sensitivity (11) suggests its potential to exert protective effects on cognitive function.”
From Type 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis (2014) · cites this paper as [11]
In the citing paper
“The putative mechanisms of MET's positive effects include (i) reducing insulin levels and improving insulin sensitivity (11), (ii) reducing inflammation (11), and (iii) reducing the risk of metabolic syndrome (25).”
From Type 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis (2014) · cites this paper as [11]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Finally, the DPP findings are also consistent with a recently reported study that demonstrated that a weight loss intervention in older individuals was associated with improved insulin sensitivity together with a relative preservation of the insulin response reflective of improved β-cell function (31) and provide a pl…”
ResultReport of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Cited by
Sorted by citations
Items 201–300 of 443
El Massry, M., Alaeddine, L. M., Ali, L., Saad, C., & Eid, A. A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908114902 · Cited by 27
Derakhshan, A., Tohidi, M., Arshi, B., Khalili, D., Azizi, F., & Hadaegh, F. (2014) · Diabetic Medicine · doi:10.1111/dme.12560 · Cited by 27
American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden, Z. T. (2008) · Diabetes Care · doi:10.2337/dc08-zb11 · Cited by 26
Threshold for Improvement in Insulin Sensitivity with Adolescent Weight Loss
Abrams, P., Katz, L. E. L., Moore, R. H., Xanthopoulos, M. S., Bishop‐Gilyard, C. T., Wadden, T. A., & Berkowitz, R. I. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.04.003 · Cited by 27
Ostroumova, O. D., Surkova, E. V., Chikh, E. V., Rebrova, E. V., & Borisov, M. S. (2018) · Diabetes Mellitus · doi:10.14341/dm9660 · Cited by 29
Zeitler, P. S. (2019) · World Journal of Pediatrics · doi:10.1007/s12519-019-00247-1 · Cited by 28
Larsen, R. N., Ali, H., Dempsey, P. C., Grace, M. S., Dillon, F., Kingwell, B. A., Cohen, N. D., Owen, N. G., GREEN, D. J., & Dunstan, D. W. (2019) · Obesity · doi:10.1002/oby.22554 · Cited by 27
Raghavan, S., Jablonski, K., Delahanty, L. M., Maruthur, N. M., Leong, A., Franks, P. W., Knowler, W. C., Florez, J. C., & Dabelea, D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14309 · Cited by 25
Xiong, X., Elkind-Hirsch, K. E., Xie, Y., Delarosa, R. L., Maney, P., Pridjian, G. C., & Buekens, P. M. (2012) · Journal of Public Health Dentistry · doi:10.1111/jphd.12004 · Cited by 25
Majithia, A. R., Jablonski, K. A., McAteer, J. B., Mather, K. J., Goldberg, R. B., Kahn, S. E., & Florez, J. C. (2011) · Diabetologia · doi:10.1007/s00125-011-2234-1 · Cited by 26
“After 1 year of DPP treatments, all of which provided an insulin-sensitising effect, proinsulin levels fell in all treatment groups compared with placebo [10].”
Soltero, E. G., Konopken, Y. P., Olson, M. L., Keller, C. S., Castro, F. G., Williams, A. N., Patrick, D. L., Ayers, S. L., Hu, P., Sandoval, M. T. P., et al. (2017) · BMC Public Health · doi:10.1186/s12889-017-4174-2 · Cited by 27
Henderson, D. C., Fan, X., Sharma, B., Copeland, P. M., Borba, C. P. C., Freudenreich, O., Cather, C., Evins, A. E., & GOFF, D. C. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000358312.99233.ef · Cited by 26
Endogenous Sex Hormone Changes in Postmenopausal Women in the Diabetes Prevention Program
Kim, C., Kong, S., Laughlin, G. A., Golden, S. H., Mather, K. J., Nan, B., Edelstein, S. L., Randolph, J. F., Labrie, F., Buschur, E., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1233 · Cited by 25
Preservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 25
Hasnain, M., Fredrickson, S. K., & Vieweg, W. V. R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110389214 · Cited by 24
“The observation in the DPP (Kitabchi et al., 2005; Perreault et al., 2009) that insulin secretion and other biological processes retained with younger age were pivotal in restoring normal glucose regulation would also favor an early use of metformin in high-risk individuals.”
BackgroundInfluentialWagner, R. J., Heni, M., Kantartzis, K., Sandforth, A., Machann, J., Schick, F., Peter, A., Fritsche, L., Szendrödi, J., Pfeiffer, A. F. H., et al. (2022) · Diabetes · doi:10.2337/db22-0441 · Cited by 25
Lee, Y., Lee, B., Chun, S., Cha, B. S., & Lee, H. C. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02755.x · Cited by 24
Diabetes, Insulin and Alzheimer's Disease
Craft, S., & Christen, Y. (2010) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-04300-0 · Cited by 24
Chen, S. J., Aikawa, C., Yoshida, R., & Matsui, T. (2015) · Physiological Reports · doi:10.14814/phy2.12477 · Cited by 23
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 23
Chen, M., Moran, L., Harrison, C. L., Ukke, G. G., Sood, S., Bennett, C., Khomami, M. B., Absetz, P., Teede, H. J., & Lim, S. S. (2021) · Obesity Reviews · doi:10.1111/obr.13340 · Cited by 27
Tanabe, N., Saito, K., Yamada, Y., Takasawa, T., Seki, N., & Suzuki, H. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.1325 · Cited by 22
Reductions in glucose among postmenopausal women who use and do not use estrogen therapy
Kim, C., Kong, S., Laughlin, G. A., Golden, S. H., Mather, K. J., Nan, B., Randolph, J. F., Edelstein, S. L., Labrie, F., Buschur, E., et al. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182703b73 · Cited by 23
Insulin resistance and management of the menopause: a clinical hypothesis in practice
Whitcroft, S. I. J., & Herriot, A. M. (2011) · Menopause international · doi:10.1258/mi.2011.011003 · Cited by 23
Retnakaran, R. R., Qi, Y., Sermer, M., Connelly, P. W., Zinman, B., & Hanley, A. J. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.04.008 · Cited by 24
Szabó, M. I., Máté, B., Csép, K., & Benedek, T. (2017) · Biochemical Genetics · doi:10.1007/s10528-017-9827-4 · Cited by 23
Metformin for overweight women at midlife: a double-blind, randomized, controlled trial
Worsley, R., Jane, F., Robinson, P. J., Bell, R. J., & Davis, S. R. (2014) · Climacteric · doi:10.3109/13697137.2014.954997 · Cited by 22
Bahijri, S., Alissa, E. M., Akbar, D. H., & Ghabrah, T. (2010) · Annals of Saudi Medicine · doi:10.4103/0256-4947.65252 · Cited by 22
Deterioration of Sleep Quality According to Glycemic Status
Hur, M., Lee, M.-K., Seong, K., & Hong, J. H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0125 · Cited by 22
“Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by insulin resistance and beta cell dysfunction [1,2].”
BackgroundExercise Interventions to Prevent and Manage Type 2 Diabetes: Physiological Mechanisms
Dela, F., Prats, C., & Helge, J. W. (2014) · Medicine and sport science/Medicine and sport · doi:10.1159/000357334 · Cited by 24
Balzer, B. W. R., Graham, C., Craig, M. E., Selvadurai, H. C., Donaghue, K. C., Brand-Miller, J. C., & Steinbeck, K. S. (2012) · Nutrients · doi:10.3390/nu4040286 · Cited by 23
“progression from IGT to type 2 diabetes [41,42].”
BackgroundGlucose Intolerance after a Recent History of Gestational Diabetes
Benhalima, K., Leuridan, L., Calewaert, P., Devlieger, R., Verhaeghe, J., & Mathieu, C. (2014) · International Journal of Endocrinology · doi:10.1155/2014/727652 · Cited by 22
Interactions between genetic background, insulin resistance and β‐cell function
Kahn, S. E., Suvag, S., Wright, L. A.-C., & Utzschneider, K. M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01650.x · Cited by 23
Osei, K., Gaillard, T. R., & Schuster, D. (2006) · Metabolism · doi:10.1016/j.metabol.2006.08.018 · Cited by 21
Billings, L. K., Jablonski, K. A., Warner, A. S., Cheng, Y.-C., McAteer, J. B., Tipton, L., Shuldiner, A. R., Ehrmann, D. A., Manning, A. K., Dabelea, D., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3429 · Cited by 20
Li, J. H., Perry, J. A., Jablonski, K. A., Srinivasan, S., Chen, L., Todd, J. N., Harden, M. V., Mercader, J. M., Pan, Q., Dawed, A. Y., et al. (2022) · Diabetes · doi:10.2337/db22-0702 · Cited by 21
Lorenzo, C., Williams, K. M., & Haffner, S. M. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03660.x · Cited by 20
The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals
Manning, P. J., Sutherland, W. H. F., Walker, R. J., Williams, S., de Jong, S. A., & Berry, E. A. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.015 · Cited by 20
Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks
ORTEGA, J. F., Morales‐Palomo, F., Ramírez-Jiménez, M., Moreno‐Cabañas, A., & Mora‐Rodríguez, R. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01488-7 · Cited by 22
Beyond Glucose—Rethinking Prediabetes for Precision Prevention
Wagner, R. J., Selvin, E., Sehgal, R., Prystupa, K., Misra, S., Fritsche, A., & Heni, M. (2025) · Diabetes Care · doi:10.2337/dci25-0054 · Cited by 23
Jagannathan, R., Snehalatha, C., Selvam, S., Nanditha, A., Shetty, A. S., Godsland, I. F., Johnston, D. G., & Ramachandran, A. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0718-z · Cited by 19
Lytrivi, M., Cauduro, C. G. D. S., Kibanda, J., Kristanto, P., Paesmans, M., & Cnop, M. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.07.018 · Cited by 20
Fetal loss and long-term maternal morbidity and mortality: A systematic review and meta-analysis
Vlachou, F., Iakovou, D., Daru, J., Khan, R. A., Pepas, L. P., Quenby, S. M., & Iliodromiti, S. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004342 · Cited by 24
Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Saraceni, C., & Broderick, T. L. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802111 · Cited by 19
Sanders, L., Dicklin, M. R., Palacios, O. M., Maki, C., Wilcox, M. L., & Maki, K. C. (2020) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12822 · Cited by 19
The development and benefits of metformin in various diseases
Dong, Y., Qi, Y., Jiang, H., Tian, M., Zhang, Y., Peng, C. S., Li, W.-C., Zhang, Y., Zhou, Y., Zang, Y., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-0998-6 · Cited by 21
Jetha, M., Nzekwu, U., Lewanczuk, R. Z., & Ball, G. (2009) · Journal of Pediatric Endocrinology & Metabolism (JPEM) · doi:10.1515/jpem.2009.22.11.1051 · Cited by 21
The Look AHEAD Study: Implications for Clinical Practice Go Beyond the Headlines
Delahanty, L. M. (2014) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.01.008 · Cited by 19
Bigazzi, R., Bianchi, S., Buoncristiani, E., & Campese, V. M. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.11.001 · Cited by 18
Ha, J., Chung, S. T., Springer, M., Kim, J. Y., Chen, P., Chhabra, A., Cree‐Green, M., Behn, C. D., Sumner, A. E., Arslanian, S. A., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00189.2023 · Cited by 18
Rong, L., Luo, N., Gong, Y., Tian, H., Sun, B., & Li, C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108683 · Cited by 17
Yoon, U., Kwok, L. L., & Magkidis, A. (2012) · BMC Proceedings · doi:10.1186/1753-6561-6-s3-p28 · Cited by 17
Placental DNA methylation changes in gestational diabetes mellitus
Chen, F., Fei, X., Zhu, W., Zhang, Z., Shen, Y., Mao, Y., Zhu, Q., Xu, J., Zhou, W., Li, M., et al. (2022) · Epigenetics · doi:10.1080/15592294.2022.2110193 · Cited by 19
Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes
Pratley, R. E. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)70004-x · Cited by 16
Tjandrawinata, R. R., Manaf, A., Malinda, D., & Susanto, L. W. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s97568 · Cited by 18
Alzahrani, S., Nelson, J., Moss, S. F., Paulus, J. K., Knowler, W. C., & Pittas, A. G. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.05.015 · Cited by 17
Lu, L., Lu, Y., Gao, C., & Zhang, N. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00582-4 · Cited by 17
Lorenzo, C., Lee, R., & Haffner, S. M. (2012) · Diabetes Care · doi:10.2337/dc11-1902 · Cited by 16
Effect of 3:7 ratio of Astragalus total saponins and Curcumin on the diabetic nephropathy rats model
Liu, B., Miao, J., Peng, M., et al. (2018) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2018.11.003 · Cited by 16
Lifestyle interventions to prevent type 2 diabetes
Goldberg, R. B. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69676-1 · Cited by 16
A systematic review of metformin to limit weight-gain with atypical antipsychotics
Lee, Y., & Jeong, J. H. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01255.x · Cited by 14
“Metformin can also cause weight loss in patients with type 2 diabetes as well as in obese non-diabetic adults (17, 18).”
BackgroundChen, Y., Shen, T., Zhong, L., Liu, Z., Dong, X., Huang, T., Wang, Q., & Xiao, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01167 · Cited by 15
“…in other studies of HCQ in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19, about 104 clinical trials are still ongoing in different countries to assess the potential effects of CQ and/or HCQ against COVID19, according to the latest reports (Koschmieder et al., 2020).”
BackgroundKoopman, R. J., Swofford, S., Beard, M. N., & Meadows, S. E. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2009.01.006 · Cited by 15
Metabolite Signature of Physical Activity and the Risk of Type 2 Diabetes in 7271 Men
Kemppainen, S., Silva, L. F., Lankinen, M. A., Schwab, U., & Laakso, M. (2022) · Metabolites · doi:10.3390/metabo12010069 · Cited by 16
“In the Diabetes Prevention Program, both decreased insulin sensitivity and insulin secretion were independently associated with the conversion to type 2 diabetes [26], but in other studies, the role of insulin secretion has remained unclear [27].”
BackgroundRationale for multiple risk intervention: the need to move from theory to practice.
Erhardt, L. (2007) · PubMed Central · Cited by 14
Management of patients with type 2 diabetes
Nelson, S. E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.611797 · Cited by 14
Hommos, N. A. A., Ebenibo, S., Edeoga, C., & Dagogo-Jack, S. E. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa164 · Cited by 15
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Newsholme, P., Rowlands, J., Rose’Meyer, R. B., & Cruzat, V. F. (2022) · Antioxidants · doi:10.3390/antiox11010108 · Cited by 14
“Metformin directly modulates pancreatic β-cell function including moderate increase in insulin release, transcriptional regulation of βcell signalling and cell viability, which is dependent on the presence of glucose [108,109].”
BackgroundThe Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity
Cusi, K. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-260-1_1 · Cited by 15
Impact of therapeutic advances on hypoglycaemia in type 2 diabetes
Boyle, P. J., & Zrebiec, J. F. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.795 · Cited by 14
“Moreover, insulin sensitivity improves if β-cell function is preserved [50], and is important for maintaining counterregulation.”
BackgroundClinical research progress on β-cell dysfunction in T2DM development in the Chinese population
Chen, Y., Jiang, Q., Xing, X., Yuan, T., & Li, P. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09914-9 · Cited by 14
Unlocking the potential: very-low-energy ketogenic therapy in obesity-related disorders
Simancas‐Racines, D., Reytor-González, C., Zambrano, A. K., Annunziata, G., Am, C., Verde, L., Frías-Toral, E., Guerra, C. V., & Hidalgo, R. (2025) · Food and Agricultural Immunology · doi:10.1080/09540105.2024.2442368 · Cited by 13
“One of the key mechanisms in prediabetes is insulin resistance, where the body’s cells (particularly in the muscles, liver, and adipose tissue) do not respond effectively to insulin, a crucial hormone for blood glucose regulation (The Diabetes Prevention Program Research Group, 2005).”
Metformin use in prediabetes: is earlier intervention better?
Warrilow, A., Somerset, S. M., Pumpa, K. L., & Fleet, R. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01559-9 · Cited by 13
“Both higher insulin secretion and sensitivity at baseline and improvements in response to treatment have been associated with lower diabetes incidence in other studies conducted on DPP data [16].”
ResultArreola, E. V., Hanson, R. L., Bogardus, C., & Knowler, W. C. (2021) · Diabetes · doi:10.2337/db21-0416 · Cited by 13
Satoh, H., Kudoh, A., Hasegawa, K., Hirai, H., & Watanabe, T. (2013) · Diabetology International · doi:10.1007/s13340-013-0150-y · Cited by 13
Investigating the pathogenesis and risk of Type 2 diabetes: clinical applications of metabolomics
Ng, T. W., Khan, A. A., & Meikle, P. J. (2012) · Clinical Lipidology · doi:10.2217/clp.12.75 · Cited by 14
Surgery for Diabetes: Clinical and Mechanistic Aspects
Kapeluto, J., Tchernof, A., & Biertho, L. D. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.05.008 · Cited by 15
Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes
Knowler, W. C., & Crandall, J. P. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1268-5 · Cited by 13
Knockout of farnesoid X receptor aggravates process of diabetic cardiomyopathy
Qiang, S., Tao, L., Zhou, J., Wang, Q., Wang, K., Lü, M., Wang, W.-F., Lin, H., Xue, S., Chen, Y., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108033 · Cited by 13
“Activation of FXR inhibits apoptosis in Barrett’s esophageal cells, but promotes apoptosis in breast cancer [18].”
Liu, Y., Guo, H., Wang, Q., Chen, J., Xuan, Y., Xu, J., Liu, Y., Sun, K., Gao, Q., Sun, Z., et al. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.12.009 · Cited by 15
Can thiazolidinediones delay disease progression in type 2 diabetes?
Leiter, L. A. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112507 · Cited by 12
Protective Effects of Moderate Intensity Static Magnetic Fields on Diabetic Mice
Li, Q., Fang, Y., Wu, N., Gu, L., Li, H., Liao, Z., Liu, M., Fang, Z., & Zhang, X. (2020) · Bioelectromagnetics · doi:10.1002/bem.22305 · Cited by 12
“The state of pancreatic tissue is particularly important for insulin secretion [Kitabchi et al., 2005].”
BackgroundHannon, T. S., Saha, C., Carroll, A. E., Palmer, K. N. B., Phillips, E. O., & Marrero, D. G. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12692 · Cited by 12
“The DPP has been shown to be effective in preventing progression of diabetes in women with former GDM and prediabetes.(4,17,18) We elected to use a group-based format that was developed by our Center to minimize the costs of intervention delivery.”
MethodBillings, L. K., Jablonski, K. A., Pan, Q., Florez, J. C., Franks, P. W., Goldberg, R. B., Hivert, M.-F., Kahn, S. E., Knowler, W. C., Lee, C. G., et al. (2024) · Diabetes · doi:10.2337/db23-0761 · Cited by 11
Erdõs, B., O’Donovan, S. D., Adriaens, M. E., Gijbels, A., Trouwborst, I., Jardon, K. M. C., Goossens, G. H., Afman, L. A., Blaak, E. E., van Riel, N. A. W., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58703-6 · Cited by 10
“In addition, changes in insulin secretion and its relation to circulating glucose levels in the development of both T1D and T2D have been reported to be non-monotonic, rendering the estimation of insulin secretion purely from glucose very challenging 45,46 .”
BackgroundHirukawa, H., Hashiramoto, M., Tanizawa, Y., Kaku, K., & Pioglitazone and Sulfonylurea Remission from Type 2 Diabetes Mellitus and Anti‐Atherosclerosis in Japan (PREVENT‐J) study group (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12813 · Cited by 10
Type 2 Diabetes Treatment in the Patient with Obesity
Malin, S. K., & Kashyap, S. R. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.007 · Cited by 11
Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?
Buse, J. B., D’Alessio, D. A., & Riddle, M. C. (2018) · Diabetes Care · doi:10.2337/dci18-0025 · Cited by 11
Festa, A., Haffner, S. M., Wagenknecht, L. E., Lorenzo, C., & Hanley, A. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1937 · Cited by 11
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 14
Franks, P. W., Huang, T. T. ‐., & Ball, G. D. C. (2007) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(07)13011-2 · Cited by 10
Shin, S., & Kim, H. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s105285 · Cited by 9
Lifestyle Approaches and Glucose Intolerance
Stull, A. J. (2014) · American Journal of Lifestyle Medicine · doi:10.1177/1559827614554186 · Cited by 10
Risk of hypoglycemia in youth with type 2 diabetes on insulin
Shahid, M., Shaibi, G. Q., Baines, H., Garcia-Filion, P. C., Gonzalez-Garcia, Z., & Olson, M. L. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0014 · Cited by 9
Shi, R., Li, X., Gao, B., Zhang, C., & Li, M. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.02.016 · Cited by 9
Prevention of Diabetes Development in Those with the Metabolic Syndrome
Tupper, T., & Gopalakrishnan, G. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.006 · Cited by 10
Using Oral Challenge Testing to Assess Insulin Action and Secretion With Mathematical Modeling
Staten, M. A., & Kelley, D. E. (2014) · Diabetes · doi:10.2337/db13-1839 · Cited by 10
Brunani, A., Caumo, A., Graci, S., Castagna, G., Viberti, G. C., & Liuzzi, A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00728.x · Cited by 9
Metadata
- Authors
- The Diabetes Prevention Program Research Group
- Affiliations
- George Washington University (US)
- Corresponding author
- The Diabetes Prevention Program Research Group
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2005-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 2404-2414
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC1360738
- OpenAlex
- W11872906
- Semantic Scholar
- 325f16dd65ffe228accc202bdf7b70e715176447
- Cited by
- 446
- References
- 49
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 16 · 2023: 19 · 2022: 14 · 2021: 19 · 2020: 19 · 2019: 18 · 2018: 22 · 2017: 17 · 2016: 26 · 2015: 24 · 2014: 26 · 2013: 17 · 2012: 31
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- National Institutes of Health
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK048489)
- National Institute of Child Health and Human Development
- National Center for Research Resources
- Office of Women's Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 2 diabetes prevention, insulin secretion, insulin sensitivity, insulin resistance, beta-cell dysfunction, impaired glucose tolerance, metformin, intensive lifestyle intervention, Diabetes Prevention Program, diabetes incidence, weight change
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Islets of Langerhans, Life Style, Male, Metformin, Middle Aged, Placebos
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
